David Wyles
Concepts (241)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antiviral Agents | 59 | 2025 | 740 | 11.800 |
Why?
| | Hepatitis C, Chronic | 32 | 2025 | 164 | 9.350 |
Why?
| | Hepacivirus | 48 | 2025 | 258 | 8.650 |
Why?
| | Hepatitis C | 29 | 2025 | 263 | 8.320 |
Why?
| | Benzimidazoles | 16 | 2020 | 169 | 4.300 |
Why?
| | Drug Resistance, Viral | 18 | 2025 | 115 | 4.100 |
Why?
| | Coinfection | 15 | 2020 | 137 | 3.060 |
Why?
| | HIV Infections | 28 | 2022 | 2830 | 3.050 |
Why?
| | Ribavirin | 15 | 2020 | 91 | 2.370 |
Why?
| | Sofosbuvir | 16 | 2022 | 59 | 2.300 |
Why?
| | Quinoxalines | 7 | 2019 | 66 | 2.280 |
Why?
| | Fluorenes | 7 | 2020 | 42 | 2.250 |
Why?
| | Sulfonamides | 13 | 2020 | 513 | 2.250 |
Why?
| | Viral Nonstructural Proteins | 10 | 2025 | 65 | 2.190 |
Why?
| | Liver Cirrhosis | 8 | 2020 | 316 | 2.160 |
Why?
| | Drug Therapy, Combination | 26 | 2020 | 1060 | 1.840 |
Why?
| | Uridine Monophosphate | 5 | 2016 | 15 | 1.700 |
Why?
| | Carbamates | 9 | 2020 | 49 | 1.480 |
Why?
| | Anti-Retroviral Agents | 5 | 2019 | 235 | 1.450 |
Why?
| | Protease Inhibitors | 10 | 2020 | 107 | 1.390 |
Why?
| | Hepatitis B, Chronic | 3 | 2019 | 24 | 1.350 |
Why?
| | Proline | 11 | 2020 | 80 | 1.270 |
Why?
| | Pyrrolidines | 9 | 2019 | 80 | 1.210 |
Why?
| | Genotype | 21 | 2025 | 1920 | 1.200 |
Why?
| | Congresses as Topic | 3 | 2021 | 233 | 1.180 |
Why?
| | Sustained Virologic Response | 11 | 2025 | 40 | 1.160 |
Why?
| | Hepatitis, Viral, Human | 3 | 2021 | 26 | 1.160 |
Why?
| | Cyclopropanes | 11 | 2020 | 90 | 0.980 |
Why?
| | Drug Users | 2 | 2024 | 41 | 0.970 |
Why?
| | Lactams, Macrocyclic | 10 | 2020 | 49 | 0.910 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 3 | 2017 | 21 | 0.810 |
Why?
| | HIV-1 | 8 | 2020 | 863 | 0.790 |
Why?
| | Treatment Failure | 6 | 2025 | 353 | 0.750 |
Why?
| | Virus Replication | 7 | 2012 | 480 | 0.740 |
Why?
| | Disease Eradication | 1 | 2020 | 5 | 0.700 |
Why?
| | Organophosphonates | 4 | 2011 | 92 | 0.690 |
Why?
| | Homosexuality, Male | 2 | 2021 | 182 | 0.680 |
Why?
| | RNA, Viral | 9 | 2025 | 653 | 0.670 |
Why?
| | Humans | 77 | 2025 | 137514 | 0.660 |
Why?
| | Anti-HIV Agents | 6 | 2020 | 775 | 0.650 |
Why?
| | Valine | 7 | 2020 | 82 | 0.640 |
Why?
| | Nucleic Acid Synthesis Inhibitors | 2 | 2015 | 16 | 0.560 |
Why?
| | Imidazoles | 2 | 2015 | 244 | 0.540 |
Why?
| | Ritonavir | 6 | 2020 | 73 | 0.540 |
Why?
| | Middle Aged | 32 | 2025 | 33355 | 0.540 |
Why?
| | Darunavir | 1 | 2017 | 18 | 0.540 |
Why?
| | Aminoisobutyric Acids | 5 | 2019 | 7 | 0.520 |
Why?
| | Uracil | 5 | 2020 | 31 | 0.510 |
Why?
| | Antiretroviral Therapy, Highly Active | 3 | 2015 | 272 | 0.500 |
Why?
| | Male | 41 | 2025 | 67718 | 0.490 |
Why?
| | Leucine | 5 | 2019 | 111 | 0.490 |
Why?
| | Treatment Outcome | 18 | 2023 | 10821 | 0.490 |
Why?
| | Anilides | 5 | 2020 | 73 | 0.490 |
Why?
| | Education, Medical, Continuing | 1 | 2016 | 126 | 0.470 |
Why?
| | Adult | 31 | 2025 | 37821 | 0.460 |
Why?
| | Biomedical Research | 1 | 2021 | 689 | 0.450 |
Why?
| | Adenine | 4 | 2020 | 268 | 0.450 |
Why?
| | Female | 39 | 2025 | 73162 | 0.440 |
Why?
| | Oligopeptides | 2 | 2013 | 273 | 0.440 |
Why?
| | Viral Load | 7 | 2020 | 462 | 0.430 |
Why?
| | Pyridazines | 1 | 2014 | 56 | 0.430 |
Why?
| | 2-Naphthylamine | 5 | 2020 | 7 | 0.420 |
Why?
| | Macrocyclic Compounds | 3 | 2019 | 9 | 0.420 |
Why?
| | Purines | 1 | 2014 | 176 | 0.410 |
Why?
| | Quinolines | 1 | 2014 | 180 | 0.400 |
Why?
| | Replicon | 3 | 2009 | 14 | 0.400 |
Why?
| | Liver | 1 | 2021 | 1940 | 0.390 |
Why?
| | Scavenger Receptors, Class B | 1 | 2012 | 14 | 0.380 |
Why?
| | Disease Management | 1 | 2016 | 625 | 0.380 |
Why?
| | Aged | 17 | 2024 | 23798 | 0.350 |
Why?
| | Mass Screening | 4 | 2025 | 1264 | 0.350 |
Why?
| | Retreatment | 2 | 2021 | 72 | 0.340 |
Why?
| | Drug Synergism | 3 | 2008 | 379 | 0.330 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 2020 | 233 | 0.300 |
Why?
| | Dideoxynucleosides | 2 | 2005 | 21 | 0.290 |
Why?
| | Liver Diseases | 2 | 2016 | 313 | 0.290 |
Why?
| | Interferon-alpha | 4 | 2013 | 198 | 0.280 |
Why?
| | Cytokines | 1 | 2015 | 2095 | 0.270 |
Why?
| | Amino Acid Substitution | 2 | 2018 | 309 | 0.260 |
Why?
| | Cytosine | 2 | 2009 | 49 | 0.260 |
Why?
| | Global Health | 2 | 2020 | 386 | 0.250 |
Why?
| | Hepatitis B virus | 2 | 2019 | 40 | 0.230 |
Why?
| | HIV | 2 | 2019 | 233 | 0.230 |
Why?
| | Herpes Simplex | 1 | 2005 | 93 | 0.230 |
Why?
| | Hepatitis | 1 | 2004 | 48 | 0.230 |
Why?
| | Alanine | 2 | 2021 | 153 | 0.210 |
Why?
| | Prevalence | 3 | 2019 | 2719 | 0.200 |
Why?
| | Interferons | 2 | 2015 | 199 | 0.200 |
Why?
| | Mutation, Missense | 3 | 2014 | 338 | 0.190 |
Why?
| | Hospitals | 2 | 2024 | 678 | 0.190 |
Why?
| | Interferon beta-1a | 1 | 2021 | 12 | 0.190 |
Why?
| | Young Adult | 10 | 2019 | 13243 | 0.190 |
Why?
| | Feasibility Studies | 1 | 2025 | 950 | 0.180 |
Why?
| | Hepatitis A | 1 | 2021 | 26 | 0.180 |
Why?
| | Phylogeny | 1 | 2025 | 898 | 0.180 |
Why?
| | Adenosine Monophosphate | 1 | 2021 | 66 | 0.180 |
Why?
| | Tenofovir | 2 | 2020 | 240 | 0.180 |
Why?
| | Hepatitis B | 1 | 2021 | 71 | 0.170 |
Why?
| | World Health Organization | 1 | 2020 | 122 | 0.170 |
Why?
| | Disease Progression | 2 | 2019 | 2755 | 0.160 |
Why?
| | Data Interpretation, Statistical | 2 | 2018 | 352 | 0.160 |
Why?
| | Polyethylene Glycols | 2 | 2015 | 640 | 0.150 |
Why?
| | Emergency Service, Hospital | 3 | 2025 | 2054 | 0.150 |
Why?
| | Esters | 2 | 2009 | 77 | 0.150 |
Why?
| | United States | 10 | 2025 | 14696 | 0.150 |
Why?
| | CD4 Lymphocyte Count | 2 | 2017 | 270 | 0.150 |
Why?
| | Ribosomes | 2 | 2010 | 174 | 0.150 |
Why?
| | Immunologic Factors | 1 | 2020 | 239 | 0.150 |
Why?
| | Nucleic Acid Conformation | 4 | 2014 | 720 | 0.140 |
Why?
| | Hospitalization | 2 | 2024 | 2197 | 0.140 |
Why?
| | Alanine Transaminase | 1 | 2018 | 158 | 0.130 |
Why?
| | DNA, Viral | 1 | 2019 | 362 | 0.130 |
Why?
| | Genes, Viral | 1 | 2016 | 88 | 0.130 |
Why?
| | DNA Mutational Analysis | 1 | 2018 | 401 | 0.130 |
Why?
| | Molecular Structure | 2 | 2008 | 508 | 0.120 |
Why?
| | Mutation | 2 | 2018 | 3964 | 0.120 |
Why?
| | Survival Analysis | 1 | 2019 | 1320 | 0.120 |
Why?
| | Patient Compliance | 1 | 2020 | 586 | 0.120 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2016 | 538 | 0.120 |
Why?
| | Adolescent | 5 | 2022 | 21555 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2066 | 0.120 |
Why?
| | Regulatory Sequences, Ribonucleic Acid | 1 | 2014 | 19 | 0.110 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2015 | 125 | 0.110 |
Why?
| | Opiate Substitution Treatment | 1 | 2016 | 147 | 0.110 |
Why?
| | Chemokines | 1 | 2015 | 229 | 0.110 |
Why?
| | Risk Assessment | 2 | 2025 | 3439 | 0.110 |
Why?
| | Chemokine CXCL10 | 1 | 2014 | 39 | 0.110 |
Why?
| | Drug Interactions | 1 | 2015 | 409 | 0.110 |
Why?
| | Phenylenediamines | 1 | 2013 | 10 | 0.110 |
Why?
| | Prospective Studies | 5 | 2025 | 7598 | 0.110 |
Why?
| | Fibrosis | 1 | 2016 | 552 | 0.110 |
Why?
| | Viral Proteins | 2 | 2014 | 346 | 0.100 |
Why?
| | Prognosis | 2 | 2019 | 4031 | 0.100 |
Why?
| | Microbial Sensitivity Tests | 2 | 2012 | 362 | 0.100 |
Why?
| | Drug Combinations | 3 | 2019 | 344 | 0.100 |
Why?
| | Quality of Life | 1 | 2025 | 2870 | 0.100 |
Why?
| | Drug Discovery | 1 | 2013 | 141 | 0.090 |
Why?
| | Administration, Oral | 1 | 2014 | 814 | 0.090 |
Why?
| | Mental Disorders | 1 | 2020 | 1083 | 0.090 |
Why?
| | Cohort Studies | 5 | 2024 | 5730 | 0.090 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 252 | 0.090 |
Why?
| | Case-Control Studies | 2 | 2017 | 3546 | 0.090 |
Why?
| | Telemedicine | 1 | 2020 | 852 | 0.090 |
Why?
| | Prodrugs | 1 | 2011 | 49 | 0.090 |
Why?
| | Models, Molecular | 3 | 2012 | 1586 | 0.090 |
Why?
| | Nucleosides | 1 | 2010 | 27 | 0.090 |
Why?
| | Riboswitch | 1 | 2012 | 67 | 0.080 |
Why?
| | Japan | 2 | 2021 | 116 | 0.080 |
Why?
| | Drug Administration Schedule | 3 | 2017 | 784 | 0.080 |
Why?
| | Cell Line, Tumor | 2 | 2008 | 3420 | 0.080 |
Why?
| | Drug Design | 1 | 2010 | 170 | 0.080 |
Why?
| | Biomarkers | 1 | 2020 | 4172 | 0.080 |
Why?
| | Cell Line | 2 | 2012 | 2852 | 0.080 |
Why?
| | Piperidines | 1 | 2010 | 208 | 0.070 |
Why?
| | Phenylthiourea | 1 | 2008 | 5 | 0.070 |
Why?
| | Body Mass Index | 1 | 2017 | 2369 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1580 | 0.070 |
Why?
| | Immunity, Innate | 1 | 2014 | 832 | 0.070 |
Why?
| | Plasmids | 1 | 2009 | 363 | 0.070 |
Why?
| | Structure-Activity Relationship | 1 | 2009 | 586 | 0.070 |
Why?
| | Inhibitory Concentration 50 | 1 | 2006 | 90 | 0.070 |
Why?
| | Luciferases | 1 | 2006 | 151 | 0.060 |
Why?
| | Genes, Reporter | 1 | 2006 | 268 | 0.060 |
Why?
| | Thailand | 1 | 2025 | 17 | 0.060 |
Why?
| | Saquinavir | 1 | 2004 | 1 | 0.060 |
Why?
| | Simplexvirus | 1 | 2005 | 80 | 0.060 |
Why?
| | Indinavir | 1 | 2004 | 7 | 0.060 |
Why?
| | Uganda | 1 | 2025 | 72 | 0.060 |
Why?
| | Nelfinavir | 1 | 2004 | 9 | 0.060 |
Why?
| | Drug Labeling | 1 | 2005 | 40 | 0.060 |
Why?
| | Nevirapine | 1 | 2004 | 17 | 0.060 |
Why?
| | Oxazines | 1 | 2004 | 30 | 0.060 |
Why?
| | Pandemics | 2 | 2024 | 1619 | 0.060 |
Why?
| | Benzoxazines | 1 | 2004 | 31 | 0.060 |
Why?
| | Lopinavir | 1 | 2004 | 30 | 0.060 |
Why?
| | Brazil | 1 | 2025 | 167 | 0.060 |
Why?
| | Alkynes | 1 | 2004 | 56 | 0.060 |
Why?
| | Zidovudine | 1 | 2004 | 78 | 0.060 |
Why?
| | Time Factors | 1 | 2015 | 6817 | 0.060 |
Why?
| | Liver Function Tests | 1 | 2004 | 114 | 0.060 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2004 | 84 | 0.060 |
Why?
| | South Africa | 1 | 2025 | 219 | 0.060 |
Why?
| | Transfection | 1 | 2006 | 948 | 0.060 |
Why?
| | Pregnancy | 1 | 2017 | 6745 | 0.050 |
Why?
| | Bone Marrow Transplantation | 1 | 2005 | 286 | 0.050 |
Why?
| | Pyrimidinones | 1 | 2004 | 114 | 0.050 |
Why?
| | Recombinant Fusion Proteins | 1 | 2006 | 665 | 0.050 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2006 | 360 | 0.050 |
Why?
| | Double-Blind Method | 2 | 2021 | 1987 | 0.050 |
Why?
| | Polyphosphates | 1 | 2022 | 36 | 0.050 |
Why?
| | Singapore | 1 | 2021 | 22 | 0.050 |
Why?
| | Republic of Korea | 1 | 2021 | 36 | 0.050 |
Why?
| | Dried Blood Spot Testing | 1 | 2022 | 103 | 0.050 |
Why?
| | Mexico | 1 | 2021 | 220 | 0.040 |
Why?
| | Retrospective Studies | 5 | 2019 | 15628 | 0.040 |
Why?
| | Protein Biosynthesis | 2 | 2014 | 434 | 0.040 |
Why?
| | Liver Neoplasms | 1 | 2006 | 786 | 0.040 |
Why?
| | Raltegravir Potassium | 1 | 2019 | 17 | 0.040 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2019 | 75 | 0.040 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2019 | 105 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2024 | 803 | 0.040 |
Why?
| | Drug Resistance, Multiple, Viral | 1 | 2017 | 11 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2857 | 0.030 |
Why?
| | Kinetics | 1 | 2020 | 1679 | 0.030 |
Why?
| | Oxygen | 1 | 2021 | 943 | 0.030 |
Why?
| | Medicaid | 1 | 2020 | 436 | 0.030 |
Why?
| | Program Evaluation | 1 | 2020 | 892 | 0.030 |
Why?
| | Incidence | 2 | 2013 | 2792 | 0.030 |
Why?
| | RNA | 1 | 2022 | 924 | 0.030 |
Why?
| | Cell-Free System | 1 | 2014 | 53 | 0.030 |
Why?
| | Hepatitis C Antibodies | 1 | 2014 | 11 | 0.030 |
Why?
| | Spain | 1 | 2014 | 41 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 849 | 0.030 |
Why?
| | Polymorphism, Genetic | 1 | 2017 | 658 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2020 | 809 | 0.030 |
Why?
| | Patient Care | 1 | 2014 | 111 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2019 | 7593 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2017 | 403 | 0.030 |
Why?
| | Withholding Treatment | 1 | 2013 | 76 | 0.030 |
Why?
| | Risk Factors | 2 | 2020 | 10356 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2014 | 244 | 0.030 |
Why?
| | Plasma | 1 | 2014 | 213 | 0.020 |
Why?
| | Fluorescence Resonance Energy Transfer | 1 | 2012 | 177 | 0.020 |
Why?
| | Virus Internalization | 1 | 2010 | 47 | 0.020 |
Why?
| | Ligands | 1 | 2012 | 665 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2013 | 1357 | 0.020 |
Why?
| | Pilot Projects | 1 | 2015 | 1703 | 0.020 |
Why?
| | Magnesium | 1 | 2009 | 159 | 0.020 |
Why?
| | Lamivudine | 1 | 2009 | 64 | 0.020 |
Why?
| | Genome, Viral | 1 | 2009 | 144 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2014 | 780 | 0.020 |
Why?
| | Logistic Models | 1 | 2013 | 2064 | 0.020 |
Why?
| | Phenotype | 1 | 2014 | 3205 | 0.020 |
Why?
| | Base Sequence | 1 | 2009 | 2180 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2013 | 2838 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2011 | 1465 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2009 | 2182 | 0.010 |
Why?
| | Animals | 2 | 2018 | 37011 | 0.010 |
Why?
| | Substance-Related Disorders | 1 | 2011 | 1079 | 0.010 |
Why?
| | Signal Transduction | 1 | 2009 | 5096 | 0.010 |
Why?
| | Mice | 1 | 2009 | 17843 | 0.010 |
Why?
|
|
Wyles's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|